



Contact: Ralph Barry, Chief Business Officer
Aegis Therapeutics LLC
1-858-618-1400 Ext. 102
Email: rbarry@aegisthera.com

Aegis Therapeutics to Present at the “TIDES” and “Drug Delivery 2006” Conferences in May 2006

SAN DIEGO, CA March 20, 2006/BusinessWire/-- Aegis Therapeutics, a leader in intranasal drug delivery, will present an overview of recent advances in nasal and transmucosal delivery of peptide, protein, and non-protein macromolecular drugs employing Aegis' Intravail™ non-invasive drug delivery technology at two upcoming conferences in May 2006. The first presentation will be given at the “TIDES – Oligonucleotide and Peptide Technology and Product Development” conference on May 1, 2006 at the La Costa Resort and Spa, Carlsbad, CA. The second presentation will be given at the Pharmaceutical Education Associates' “Drug Delivery 2006” conference on May 18, 2006, at the Hilton San Diego/Del Mar, San Diego, CA.

Information about the “TIDES” and “Drug Delivery 2006” conferences may be obtained from the following websites respectively: www.ibclifesciences.com/3104 and <http://www.pharmedassociates.com/drug.asp#p255>

About Aegis Therapeutics

Aegis Therapeutics LLC is a specialty pharmaceutical company commercializing its patented Intravail™ drug delivery technology that enables the non-invasive delivery of a broad range of protein, peptide and non-peptide macromolecular therapeutics that can currently only be administered by injection. Aegis' Intravail™ absorption enhancement agents are mild and non-irritating to mucosal membranes. They provide exceptionally high and unmatched bioavailability performance, comparable in efficiency to subcutaneous injection, via the intranasal and other mucosal membrane administration routes. Intravail™ also provides for rapid drug absorption and onset of action, controlled transient permeation of the nasal mucosal barrier, avoidance of gastric hydrolysis and "first pass effect" elimination by the liver, greater patient convenience and compliance, elimination of needle-stick injuries and associated transmission of blood borne pathogens, compatibility with current nasal delivery devices, and ease of formulation, scale-up, and production. For more information about Aegis, please visit the Aegis website at: <http://www.aegisthera.com>.

###